Biotechnology company Cha Bio Tech, 300 billion KRW capital increase with Kakao participating alone... A signal flare for the biotechnology and platform alliance?

The KOSDAQ-listed company Cha Bio Tec decided on November 19 to implement a third-party paid capital increase of approximately 30 billion KRW. This financing is interpreted as aimed at acquiring other corporate securities and stabilizing operational strategies and finances.

In this paid capital increase, Cha Bio Tec plans to issue 2,400,192 common shares at a price of 12,499 won per share. Based on the stock issuance price, the total amount of funds raised is approximately 30 billion won. The new shares will be allocated to external investor Kakao Corporation, conducted in the form of exclusive investment.

Cha Bio Tec is one of the representative biotech companies listed on the KOSDAQ, specializing in the development of biopharmaceuticals and research on stem cell therapies. Recently, it has been accelerating the expansion of new research and development pipelines and related corporate investments, and this paid-in capital increase is also seen as part of its business strategy.

It is worth noting that Kakao participated in this paid capital increase. Recently, in addition to its platform business, the company has been speculated to possibly venture into new growth areas such as digital healthcare and the biotechnology industry. Through this investment, the possibility of establishing a strategic alliance with Cha Bio Tec cannot be ruled out, which is attracting significant attention from the industry.

According to the subsequent actual application direction of the raised funds by Cha Bio Tec, the long-term corporate value may change. If the partnership with Kakao becomes clearer, it is expected to establish a new paradigm of cooperative relationships in the biotechnology industry.